Ann: Trading Halt, page-37

Capricor our nearest competitor

At six months, Per had a 2.9 point difference, versus around a 3.7 point difference Cap at 3 years here. Whether 2.9 in six months is better than 3.7 in 3 years is complex - it’s not exactly a like for like comparison. As another key difference is that patients on our study didn’t deteriorate, whereas those on the Capricor study did, albeit our data is only for six months.
Think outside the sq
The parties who have contributed to this CR must be confident that our DMD drug ( avircursen is superior to Cap1002 )
We are talking about mega $$$ invested by whoever
So relax everyone